Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial
Jean Courcier, Cécile Dalban, Brigitte Laguerre, Sylvain Ladoire, Philippe Barthélémy, Stéphane Oudard, Florence Joly, Gwénaëlle Gravis, Christine Chevreau, L. Geoffrois, Élise Deluche, Frédéric Rolland, Delphine Topart, Stéphane Culine, Sylvie Négrier, Hakim Mahammedi, Florence Tantot, Antoine Jamet, Bernard Escudier, Ronan Flippot, Laurence Albigès
Topics & Concepts
MedicineNivolumabRenal cell carcinomaInternal medicineKidney cancerNephrectomyOncologyConfidence intervalAdverse effectCarcinomaResponse Evaluation Criteria in Solid TumorsUrologyCancerClinical trialKidneyPhases of clinical researchImmunotherapyRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments